Deployment of convalescent plasma for the prevention and treatment of COVID-19.

@article{Bloch2020DeploymentOC,
  title={Deployment of convalescent plasma for the prevention and treatment of COVID-19.},
  author={Evan M. Bloch and Shmuel Shoham and Arturo Casadevall and Bruce S. Sachais and Beth H. Shaz and Jeffrey L. Winters and Camille M. van Buskirk and Brenda J Grossman and Michael J. Joyner and Jeffrey P Henderson and Andrew S. Pekosz and Bryan Lau and Amy Wesolowski and Louis M. Katz and Hua Shan and Paul G. Auwaerter and David Thomas and David J Sullivan and Nigel S Paneth and Eric A Gehrie and Steven L. Spitalnik and Eldad A Hod and Lew Pollack and Wayne T Nicholson and Liise-Anne Pirofski and Jeffrey A. Bailey and Aaron A. R. Tobian},
  journal={The Journal of clinical investigation},
  year={2020}
}
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease (COVID-19), has spurred a global health crisis. To date, there are no proven options for prophylaxis for those who have been exposed to SARS-CoV-2, nor therapy for those who develop COVID-19. Immune (i.e. "convalescent") plasma refers to plasma that is collected from individuals, following resolution of infection and development of antibodies. Passive antibody administration through transfusion of… Expand

Paper Mentions

Interventional Clinical Trial
Open label two arms, non randomized Convalescent Plasma treatment to severe and critical pneumonia COVID-19 hospitlaized patients compared to a historical cohort with matched… Expand
ConditionsCovid-19
InterventionBiological
Observational Clinical Trial
This is the first Case Studies article highlight factors determine the effectiveness of Convalescent Plasma Therapy (CPT) in Indonesia, accompanied by supporting data and images… Expand
ConditionsInfectious Disease
InterventionBiological
Interventional Clinical Trial
Background: On December 2019, a new human coronavirus infection (COVID-19) was detected in China. Its infectivity and virulence characteristics caused a rapid spread, being declared… Expand
ConditionsCOVID-19 Pneumonia
InterventionDrug
Convalescent Plasma Therapy Against Covid- 19: A Comprehensive Review
The pandemic COVID-19, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to create havoc all over the world having caused more than 40 million cases and more thanExpand
The Progress and Challenges of Convalescent Plasma Therapy for Coronavirus Disease 2019
Abstract Middle East respiratory syndrome (MERS), severe acute respiratory syndrome (SARS), and SARS-CoV-2 infection (causing coronavirus disease 2019 [COVID-19]) are serious diseases. To date, noExpand
Convalescent COVID-19 plasma
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a new human disease. December 31, 2019 marked the day the World Health OrganizationExpand
Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19
TLDR
An overview of the historical uses of convalescent plasma therapy, summarizes current evidence for convalescence plasma use for COVID-19, and highlights future antibody therapies are summarized. Expand
The Emerging Role of Convalescent Plasma in the Treatment of COVID-19
TLDR
Preliminary evidence from case series is favorable as significant clinical, biochemical improvement and hospital discharge have been reported, and convalescent plasma seems to be a safe option, but potential risks such as transfusion-related acute lung injury and antibody-dependent enhancement are discussed. Expand
Anti-SARS-CoV-2 hyperimmune plasma workflow
TLDR
The general indications for drawing up clinical protocols for the integral management of "COVID-19-convalescent plasma" for which the validation and approval of the Ethics Committees is still necessary are below. Expand
Convalescent Plasma Therapy for COVID-19: Current Status and Future Directions
TLDR
Convalescent plasma (CP), which refers to plasma collected from individuals recovered from an illness and developed antibodies against the pathogen, is also being proposed as a therapeutic option for COVID-19 treatment in severe cases to achieve short-term immunity against the virus. Expand
Convalescent Plasma – Is it Useful for Treating SARS Co-V2 infection?
TLDR
Current guidelines for the use of CP in SARS-CoV-2 infection are reviewed and various guidelines of different agencies are compared. Expand
Convalescent plasma: A possible treatment of COVID-19 in India.
TLDR
Drawn from current patients who are infected with COVID-19, its CP (human anti-SARS-CoV-2 plasma) might be one way to modulate the infectivity of this virus or its effects postinfection. Expand
Convalescent Plasma a Potential Therapy in Covid-19 Patients in Low Resource Setting: Rapid Review
TLDR
Convalescent plasma therapy is a very promising treatment approach for COVID-19 patients; however, more clinical trials are required to validate the effectiveness of this therapy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 76 REFERENCES
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
TLDR
In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status, and these observations require evaluation in clinical trials. Expand
Challenges of Convalescent Plasma Infusion Therapy in Middle East Respiratory Coronavirus Infection: A Single Centre Experience
TLDR
For effective CP infusion in MERS, donor plasma with a neutralization activity of a PRNT titre ≥1:80 should be used and ELISA IgG could substitute for the neutralization test in resource-limited situations. Expand
The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study
TLDR
CP therapy was welltolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases, but the optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials. Expand
Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital
TLDR
All infected HCW whose condition had progressed severely and who had failed to respond to the available treatment, survived after transfusion with convalescent plasma after real-time quantitative RT–PCR for SARS-CoV. Expand
A serological assay to detect SARS-CoV-2 seroconversion in humans
TLDR
Serological assays are of critical importance to determine seroprevalence in a given population, define previous exposure and identify highly reactive human donors for the generation of convalescent serum as therapeutic. Expand
Is COVID-19 receiving ADE from other coronaviruses?
  • J. Tetro
  • Medicine, Biology
  • Microbes and Infection
  • 2020
Abstract One of the most perplexing questions regarding the current COVID-19 coronavirus epidemic is the discrepancy between the severity of cases observed in the Hubei province of China andExpand
Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 — United States, January–February 2020
TLDR
On January 20, state and local health departments in the United States began identifying and monitoring all persons considered to have had close contact with patients with confirmed COVID-19, to ensure rapid evaluation and care of patients, limit further transmission, and better understand risk factors for transmission. Expand
Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China
TLDR
Overall, this dataset suggests that critical disease is rare in children with COVID-19, however younger children appeared to have higher severity of disease than adults, and emergency physicians should use caution with infants and young children. Expand
The convalescent sera option for containing COVID-19.
TLDR
The efforts in design and synthesis which led to submicromolar covalent inhibitors when the enzymatic activity of the viral protease was used as a screening platform are reported. Expand
SARS-CoV-2 specific antibody responses in COVID-19 patients
TLDR
It is demonstrated that most PCR-confirmed SARS-CoV-2 infected individuals seroconverted, as revealed by sensitive and specific in-house ELISAs, and that commercial S1 IgG or IgA ELisAs were of lower specificity while sensitivity varied between the two, with IgA showing higher sensitivity. Expand
...
1
2
3
4
5
...